Small-molecule inhibitors of GSK-3: Structural insights and their application to Alzheimer's disease models

International Journal of Alzheimer's Disease

Volumn , Issue , 2012, Pages

  Kramer, Thomas ^a   Schmidt, Boris ^a   Lo Monte, Fabio ^a  

^a DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 METHOXYBENZYL) 3 (5 NITRO 2 THIAZOLYL)UREA; 2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; CEP 16805; CG 301338; CHIR 98014; DIBROMOCANTHARELLINE; FUROPYRIMIDINE DERIVATIVE; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; HYMENIALDISINE; INDIRUBIN 3' MONOXIME; INDOLE DERIVATIVE; LITHIUM CHLORIDE; MALEIMIDE DERIVATIVE; MANZAMINE A; MERIDIANIN D; NP 103; ORGANOMETALLIC INHIBITOR; OXADIAZOLE DERIVATIVE; PAULLONE DERIVATIVE; PROPENTOFYLLINE; PYRAZOLAMIDE DERIVATIVE; PYRIMIDINE DERIVATIVE; SAR 502250; STAUROSPORINE; THIAZOLE DERIVATIVE; TIDEGLUSIB; UNCLASSIFIED DRUG; XD 4241;

ALZHEIMER DISEASE; DRUG PROTEIN BINDING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW;

EID: 84861023806     PISSN: None     EISSN: 20900252     Source Type: Journal    
DOI: 10.1155/2012/381029     Document Type: Review

References (173)

1. Chico L. K., van Eldik L. J., Watterson D. M., Targeting protein kinases in central nervous system disorders Nature Reviews Drug Discovery 2009 8 11 892 909
2. Bossemeyer D., Protein kinasesstructure and function The FEBS Letters 1995 369 1 57 61
3. Peifer C., Alessi D. R., Small-molecule inhibitors of PDK1 ChemMedChem 2008 3 12 1810 1838
4. Hooper C., Killick R., Lovestone S., The GSK3 hypothesis of Alzheimer's disease Journal of Neurochemistry 2008 104 6 1433 1439 (Pubitemid 351316776)
5. Ferrer I., Gomez-Isla T., Puig B., Freixes M., Ribé E., Dalf E., Avila J., Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies Current Alzheimer Research 2005 2 1 3 18 (Pubitemid 41389255)
6. Hernandez F., Gomez de Barreda E., Fuster-Matanzo A., Lucas J. J., Avila J., GSK3: a possible link between beta amyloid peptide and tau protein Experimental Neurology 2010 223 2 322 325
7. Leroy A., Landrieu I., Huvent I., Legrand D., Codeville B., Wieruszeski J. M., Lippens G., Spectroscopic studies of GSK phosphorylation of the neuronal tau protein and its interaction with the N-terminal domain of apolipoprotein E The Journal of Biological Chemistry 2010 285 43 33435 33444
8. Martinez A., Castro A., Dorronsoro I., Alonso M., Glycogen synthase kinase-3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation Medicinal Research Reviews 2002 22 4 373 384 (Pubitemid 34620473)
9. Eldar-Finkelman H., Glycogen synthase kinase-3: an emerging therapeutic target Trends in Molecular Medicine 2002 8 3 126 132 (Pubitemid 34532638)
10. Frame S., Cohen P., GSK3 takes centre stage more than 20 years after its discovery Biochemical Journal 2001 359 1 1 16 (Pubitemid 32939202)
11. Alzheimer A., ber eine eigenartige Erkrankung der Hirnrinde Allgemeine Zeitschrift fr Psychiatrie und psychisch-gerichtiliche Medizin 1907 64 146 148
12. Stelzmann R. A., Schnitzlein H. N., Murtagh F. R., An English translation of Alzheimer's 1907 paper, 'uber eine eigenartige erkankung der hirnrinde' Clinical Anatomy 1995 8 6 429 431
13. Dickson D., R. O. Weller, Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders 2011 2nd Wiley-Blackwell
14. Duyckaerts C., Delatour B., Potier M. C., Classification and basic pathology of Alzheimer disease Acta Neuropathologica 2009 118 1 5 36
15. Mazanetz M. P., Fischer P. M., Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases Nature Reviews Drug Discovery 2007 6 6 464 479 (Pubitemid 47064569)
16. Hernndez F., Avila J., The role of glycogen synthase kinase-3 in the early stages of Alzheimers' disease The FEBS Letters 2008 582 28 3848 3854
17. Cohen P., Goedert M., GSK3 inhibitors: development and therapeutic potential Nature Reviews Drug Discovery 2004 3 6 479 487 (Pubitemid 38807530)
18. Sereno L., Coma M., Rodriguez M., A novel GSK-3 inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo Neurobiology of Disease 2009 35 3 359 367
19. Takashima A., Drug development targeting the glycogen synthase kinase- (GSK- 3 )-mediated signal transduction pathway: role of GSK- in adult brain Journal of Pharmacological Sciences 2009 109 2 174 178
20. Spittaels K., van den Haute C., van Dorpe J., Geerts H., Mercken M., Bruynseels K., Lasrado R., Vandezande K., Laenen I., Boon T., van Lint J., Vandenheede J., Moechars D., Loos R., van Leuven F., Glycogen synthase kinase- phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice The Journal of Biological Chemistry 2000 275 52 41340 41349 (Pubitemid 32054968)
21. Bhat R. V., Budd Haeberlein S. L., Avila J., Glycogen synthase kinase-3: a drug target for CNS therapies Journal of Neurochemistry 2004 89 6 1313 1317 (Pubitemid 38802652)
22. Feng L., Geisselbrecht Y., Blanck S., Wilbuer A., Atilla-Gokcumen G. E., Filippakopoulos P., Kraling K., Celik M. A., Harms K., Maksimoska J., Marmorstein R., Frenking G., Knapp S., Essen L. O., Meggers E., Structurally sophisticated octahedral metal complexes as highly selective protein kinase inhibitors Journal of the American Chemical Society 2011 133 15 5976 5986
23. Eldar-Finkelman H., Licht-Murava A., Pietrokovski S., Eisenstein M., Substrate competitive GSK-3 Inhibitorsstrategy and Implications Biochimica et Biophysica Acta 2010 1804 3 598 603
24. Martinez A., Alonso M., Castro A., Perez C., Moreno F. J., First non-ATP competitive glycogen synthase kinase-3 (GSK- ) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease Journal of Medicinal Chemistry 2002 45 6 1292 1299 (Pubitemid 34263565)
25. Martinez A., Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs Medicinal Research Reviews 2008 28 5 773 796
26. Mora A., Sabio G., Gonzalez-Polo R. A., Cuenda A., Alessi D. R., Alonso J. C., Fuentes J. M., Soler G., Centeno F., Lithium inhibits caspase 3 activation and dephosphorylation of PKB and GSK3 induced by K + deprivation in cerebellar granule cells Journal of Neurochemistry 2001 78 1 199 206 (Pubitemid 32622601)
27. Ryves W. J., Harwood A. J., Lithium inhibits glycogen synthase kinase-3 by competition for magnesium Biochemical and Biophysical Research Communications 2001 280 3 720 725 (Pubitemid 32924489)
28. Bax B., Carter P. S., Lewis C., Guy A. R., Bridges A., Tanner R., Pettman G., Mannix C., Culbert A. A., Brown M. J. B., Smith D. G., Reith A. D., The structure of phosphorylated GSK- complexed with a peptide, FRATtide, that inhibits -catenin phosphorylation Structure 2001 9 12 1143 1152 (Pubitemid 34025049)
29. Domnguez J. M., Fuertes A., Orozco L., del Monte-Milln M., Delgado E., Medina M., Evidence for the irreversible inhibition of glycogen synthase kinas-3 by tideglusib The Journal of Biological Chemistry 2012 287 893 904
30. Smith D. G., Buffet M., Fenwick A. E., Haigh D., Ife R. J., Saunders M., Slingsby B. P., Stacey R., Ward R. W., 3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3) Bioorganic and Medicinal Chemistry Letters 2001 11 5 635 639 (Pubitemid 32187945)
31. Bertrand J. A., Thieffine S., Vulpetti A., Cristiani C., Valsasina B., Knapp S., Kalisz H. M., Flocco M., Structural characterization of the GSK- active site using selective and non-selective ATP-mimetic inhibitors Journal of Molecular Biology 2003 333 2 393 407 (Pubitemid 37188580)
32. Coghlan M. P., Culbert A. A., Cross D. A. E., Corcoran S. L., Yates J. W., Pearce N. J., Rausch O. L., Murphy G. J., Carter P. S., Roxbee Cox L., Mills D., Brown M. J., Haigh D., Ward R. W., Smith D. G., Murray K. J., Reith A. D., Holder J. C., Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription Chemistry and Biology 2000 7 10 793 803
33. Cross D. A. E., Culbert A. A., Chalmers K. A., Facci L., Skaper S. D., Reith A. D., Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death Journal of Neurochemistry 2001 77 1 94 102 (Pubitemid 32245083)
34. Selenica M. L., Jensen H. S., Larsen A. K., Pedersen M. L., Helboe L., Leist M., Lotharius J., Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation British Journal of Pharmacology 2007 152 6 959 979 (Pubitemid 350100498)
35. O'Neill D. J., Shen L., Prouty C., Conway B. R., Westover L., Xu J. Z., Zhang H. C., Maryanoff B. E., Murray W. V., Demarest K. T., Kuo G. H., Design, synthesis, and biological evaluation of novel 7-azaindolyl-heteroaryl-maleimides as potent and selective glycogen synthase kinase- (GSK- ) inhibitors Bioorganic and Medicinal Chemistry 2004 12 12 3167 3185 (Pubitemid 38680706)
36. Zhang H. C., Ye H., Conway B. R., Derian C. K., Addo M. F., Kuo G. H., Hecker L. R., Croll D. R., Li J., Westover L., Xu J. Z., Look R., Demarest K. T., Andrade-Gordon P., Damiano B. P., Maryanoff B. E., 3-(7-Azaindolyl)-4- arylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3 Bioorganic and Medicinal Chemistry Letters 2004 14 12 3245 3250 (Pubitemid 38624601)
37. Engler T. A., Henry J. R., Malhotra S., Cunningham B., Furness K., Brozinick J., Burkholder T. P., Clay M. P., Clayton J., Diefenbacher C., Hawkins E., Iversen P. W., Li Y., Lindstrom T. D., Marquart A. L., McLean J., Mendel D., Misener E., Briere D., O'Toole J. C., Porter W. J., Queener S., Reel J. K., Owens R. A., Brier R. A., Eessalu T. E., Wagner J. R., Campbell R. M., Vaughn R., Substituted 3-imidazo[1,2-a]pyridin-3-yl-4-(1,2,3,4-tetrahydro-[1,4] diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3 Journal of Medicinal Chemistry 2004 47 16 3934 3937 (Pubitemid 38970955)
38. Engler T. A., Malhotra S., Burkholder T. P., Henry J. R., Mendel D., Porter W. J., Furness K., Diefenbacher C., Marquart A., Reel J. K., Li Y., Clayton J., Cunningham B., McLean J., O'Toole J. C., Brozinick J., Hawkins E., Misener E., Briere D., Brier R. A., Wagner J. R., Campbell R. M., Anderson B. D., Vaughn R., Bennett D. B., Meier T. I., Cook J. A., The development of potent and selective bisarylmaleimide GSK3 inhibitors Bioorganic and Medicinal Chemistry Letters 2005 15 4 899 903 (Pubitemid 40458620)
39. Ye Q., Xu G., Lv D., Cheng Z., Li J., Hu Y., Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase- (GSK- ) inhibitors Bioorganic and Medicinal Chemistry 2009 17 13 4302 4312
40. Gong L., Hirschfeld D., Tan Y. C., Heather Hogg J., Peltz G., Avnur Z., Dunten P., Discovery of potent and bioavailable GSK- inhibitors Bioorganic and Medicinal Chemistry Letters 2010 20 5 1693 1696
41. Perez D. I., Palomo V., Perez C., Gil C., Dans P. D., Luque F. J., Conde S., Martinez A., Switching reversibility to irreversibility in glycogen synthase kinase-3 inhibitors: clues for specific design of new compounds Journal of Medicinal Chemistry 2011 54 12 4042 4056
42. Hers I., Tavare J. M., Denton R. M., The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity The FEBS Letters 1999 460 3 433 436 (Pubitemid 29518414)
43. Kuo G. H., Prouty C., de Angelis A., Shen L., O'Neill D. J., Shah C., Connolly P. J., Murray W. V., Conway B. R., Cheung P., Westover L., Xu J. Z., Look R. A., Demarest K. T., Emanuel S., Middleton S. A., Jolliffe L., Beavers M. P., Chen X., Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase- inhibitors Journal of Medicinal Chemistry 2003 46 19 4021 4031 (Pubitemid 37122448)
44. Zhang H. C., White K. B., Ye H., McComsey D. F., Derian C. K., Addo M. F., Andrade-Gordon P., Eckardt A. J., Conway B. R., Westover L., Xu J. Z., Look R., Demarest K. T., Emanuel S., Maryanoff B. E., Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3 Bioorganic and Medicinal Chemistry Letters 2003 13 18 3049 3053 (Pubitemid 36993634)
45. Shen L., Prouty C., Conway B. R., Westover L., Xu J. Z., Look R. A., Chen X., Beavers M. P., Roberts J., Murray W. V., Demarest K. T., Kuo G. H., Synthesis and biological evaluation of novel macrocyclic bis-7- azaindolylmaleimides as potent and highly selective glycogen synthase kinase- (GSK- ) inhibitors Bioorganic and Medicinal Chemistry 2004 12 5 1239 1255 (Pubitemid 38251315)
46. Zhang H. C., Bonaga L. V. R., Ye H., Derian C. K., Damiano B. P., Maryanoff B. E., Novel bis(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3 Bioorganic and Medicinal Chemistry Letters 2007 17 10 2863 2868 (Pubitemid 46636245)
47. Kozikowski A. P., Gaisina I. N., Yuan H., Petukhov P. A., Blond S. Y., Fedolak A., Caldarone B., McGonigle P., Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. Possible new GSK- therapies for bipolar disorders Journal of the American Chemical Society 2007 129 26 8328 8332 (Pubitemid 47035143)
48. Gaisina I. N., Gallier F., Ougolkov A. V., Kim K. H., Kurome T., Guo S., Holzle D., Luchini D. N., Blond S. Y., Billadeau D. D., Kozikowski A. P., From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase- inhibitors that suppress proliferation and survival of pancreatic cancer cells Journal of Medicinal Chemistry 2009 52 7 1853 1863
49. Zhong H., Zou H., Semenov M. V., Moshinsky D., He X., Huang H., Li S., Quan J., Yang Z., Lin S., Characterization and development of novel small-molecules inhibiting GSK3 and activating Wnt signaling Molecular Biosystems 2009 5 11 1356 1360
50. Zou H., Zhou L., Li Y., Cui Y., Zhong H., Pan Z., Yang Z., Quan J., Benzo[e]isoindole-1,3-diones as potential inhibitors of glycogen synthase kinase-3 (GSK-3). Synthesis, kinase inhibitory activity, zebrafish phenotype, and modeling of binding mode Journal of Medicinal Chemistry 2010 53 3 994 1003
51. Kozikowski A., Gaysina I., 3-Benzofuranyl-4-indolyl maleimides as potent GSK3 inhibitors for neurogenerative disorders WO 2008 2008/077138 A1
52. Kozikowski A., Gaysina I., Benzofuran-3-yl(indol-3-yl) maleimides as potent GSK3 inhibitors US 2010 2010/0004308 A1
53. von Matt P., Wagner J., Indolylmaleimide derivatives EP 2009 2075249 A2 Novartis AG.
54. Zhang H., Maryanoff B., Ye H., Substituted indazoly(indoly)maleimide derivatives as kinase inhibitors US 2008 7439363 B2 Janssen Pharmaceutica N.V.
55. Zhang H., Maryanoff B., Ye H., Substituted indazolyl (indolyl) maleimide derivatives as kinase inhibitors EP 2008 1654255 B1 Janssen Pharmaceutica N.V.
56. Omura S., Iwai Y., Hirano A., A new alkaloid AM 2282 of Streptomyces origin taxonomy, fermentation, isolation and preliminary characterization Journal of Antibiotics 1977 30 4 275 282 (Pubitemid 8119845)
57. Funato N., Takayanagi H., Konda Y., Toda Y., Harigaya Y., Iwai Y., Omura S., Absolute configuration of staurosporine by X-ray analysis Tetrahedron Letters 1994 35 8 1251 1254 (Pubitemid 24088134)
58. Leclerc S., Garnier M., Hoessel R., Marko D., Bibb J. A., Snyder G. L., Greengard P., Biernat J., Wu Y. Z., Mandelkow E. M., Eisenbrand G., Meijert L., Indirubins inhibit glycogen synthase kinase- and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? The Journal of Biological Chemistry 2001 276 1 251 260 (Pubitemid 32050314)
59. Bregman H., Williams D. S., Atilla G. E., Carroll P. J., Meggers E., An organometallic inhibitor for glycogen synthase kinase-3 Journal of the American Chemical Society 2004 126 42 13594 13595 (Pubitemid 39407220)
60. Atilla-Gokcumen G. E., Williams D. S., Bregman H., Pagano N., Meggers E., Organometallic compounds with biological activity: a very selective and highly potent cellular inhibitor for glycogen synthase kinase-3 ChemBioChem 2006 7 9 1443 1450 (Pubitemid 44375843)
61. Atilla-Gokcumen G. E., Pagano N., Streu C., Maksimoska J., Filippakopoulos P., Knapp S., Meggers E., Extremely tight binding of a ruthenium complex to glycogen synthase kinase-3 ChemBioChem 2008 9 18 2933 2936
62. Atilla-Gokcumen G. E., di Costanzo L., Meggers E., Structure of anticancer ruthenium half-sandwich complex bound to glycogen synthase kinase-3 Journal of Biological Inorganic Chemistry 2011 16 1 45 50
63. Meijer L., Skaltsounis A. L., Magiatis P., Polychronopoulos P., Knockaert M., Leost M., Ryan X. P., Vonica C. A., Brivanlou A., Dajani R., Crovace C., Tarricone C., Musacchio A., Roe S. M., Pearl L., Greengard P., GSK-3-selective inhibitors derived from Tyrian purple indirubins Chemistry and Biology 2003 10 12 1255 1266 (Pubitemid 38050973)
64. Polychronopoulos P., Magiatis P., Skaltsounis A. L., Myrianthopoulos V., Mikros E., Tarricone A., Musacchio A., Roe S. M., Pearl L., Leost M., Greengard P., Meijer L., Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases Journal of Medicinal Chemistry 2004 47 4 935 946 (Pubitemid 38176796)
65. Vougogiannopoulou K., Ferandin Y., Bettayeb K., Myrianthopoulos V., Lozach O., Fan Y., Johnson C. H., Magiatis P., Skaltsounis A. L., Mikros E., Meijer L., Soluble 3′,6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase-3 alter circadian period Journal of Medicinal Chemistry 2008 51 20 6421 6431
66. Beauchard A., Laborie H., Rouillard H., Lozach O., Ferandin Y., Guevel R. L., Guguen-Guillouzo C., Meijer L., Besson T., Thiery V., Synthesis and kinase inhibitory activity of novel substituted indigoids Bioorganic and Medicinal Chemistry 2009 17 17 6257 6263
67. Beher D., Bettai M., Churcher I., 1-alkyl-3-thio-substituted indole-2-alkynoic acids useful for the treatment for Alzheimer's disease and related conditions EP 2009 1708997 B1 Merck and Company, Inc.
68. Berg S., Hellberg S., Nylf M., Xue Y., 3-Heterocyclyl-indole inhibitors of glycogen synthase kinase-3 US 2008 7399780 B2 Astra Zeneca AB.
69. Berg S., Hellberg S., Nylf M., Xue Y., 2-hydroxy-3-heteroarylindole derivatives as GSK3 inhibitors EP 2008 1492785 B1 Astra Zeneca AB.
70. Green J., Miller A., Jimenez J., Azaindoles useful as inhibitors of rock and other protein kinases US 2009 7514448 B2 Vertex Pharmaceuticals Inc.
71. Heckel A., Roth G., Kley J., Hoerer S., Uphues I., Novel alkyl-containing 5-acylindolinones, their preparation and their use as pharmaceutical products WO 2005 2005/087727 A1 Boehringer Ingelheim Pharma GmbH Company KG.
72. Heckel A., Roth G., Kley J., Hoerer S., Uphues I., Cycloalkylcontaining 5-acylindolinones, the preparation thereof and their use as medicaments WO 2007 7262206 B2 Boehringer Ingelheim International GmbH.
73. Heckel A., Roth G., Kley J., Hoerer S., Uphues I., Aryl-containing 5-acylindolinones, the preparation thereof and their use as medicaments US 2007 7176231 B2 Boehringer Ingelheim International GmbH.
74. Heckel A., Roth G., Kley J., Hoerer S., Uphues I., Alkyl-containing 5-acylindolinones, the preparation thereof and their use as medicaments US 2009 7560480 B2 Boehringer Ingelheim Pharma GmbH Company KG.
75. Meijer L., Greengard P., Knockaert M., Skaltsounis A., Indirubin-type compounds, compositions, and methods for their use US 2007 2007/0276025 A1
76. Leost M., Schultz C., Link A., Wu Y. Z., Biernat J., Mandelkow E. M., Bibb J. A., Snyder G. L., Greengard P., Zaharevitz D. W., Gussio R., Senderowicz A. M., Sausville E. A., Kunick C., Meijer L., Paullones are potent inhibitors of glycogen synthase kinase- and cyclin-dependent kinase 5/p25 European Journal of Biochemistry 2000 267 19 5983 5994
77. Schultz C., Link A., Leost M., Zaharevitz D. W., Gussio R., Sausville E. A., Meijer L., Kunick C., Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity Journal of Medicinal Chemistry 1999 42 15 2909 2919 (Pubitemid 29370435)
78. Knockaert M., Wieking K., Schmitt S., Leost M., Grant K. M., Mottram J. C., Kunick C., Meijer L., Intracellular targets of paullones: identification following affinity purification on immobilized inhibitor The Journal of Biological Chemistry 2002 277 28 25493 25501 (Pubitemid 34951864)
79. Kunick C., Lauenroth K., Leost M., Meijer L., Lemcke T., 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase- Bioorganic and Medicinal Chemistry Letters 2004 14 2 413 416 (Pubitemid 38045135)
80. Kunick C., Zeng Z., Gussio R., Zaharevitz D., Leost M., Totzke F., Schachtele C., Kubbutat M. H. G., Meijer L., Lemcke T., Structure-aided of optimization of kinase inhibitors derived from alsterpaullone ChemBioChem 2005 6 3 541 549 (Pubitemid 40868143)
81. Meijer L., Kunick C., Use of paullone derivatives for making medicines WO 2001 2001/060374 A1
82. Witherington J., Bordas V., Garland S. L., Hickey D. M. B., Ife R. J., Liddle J., Saunders M., Smith D. G., Ward R. W., 5-Aryl-pyrazolo[3,4-b] pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3) Bioorganic and Medicinal Chemistry Letters 2003 13 9 1577 1580 (Pubitemid 36428564)
83. Witherington J., Bordas V., Haigh D., Hickey D. M. B., Ife R. J., Rawlings A. D., Slingsby B. P., Smith D. G., Ward R. W., 5-Aryl-pyrazolo[3,4-b] pyridazines: potent inhibitors of glycogen synthase kinase-3 (GSK-3) Bioorganic and Medicinal Chemistry Letters 2003 13 9 1581 1584 (Pubitemid 36428565)
84. Witherington J., Bordas V., Gaiba A., Garton N. S., Naylor A., Rawlings A. D., Slingsby B. P., Smith D. G., Takle A. K., Ward R. W., 6-Aryl-pyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3) Bioorganic and Medicinal Chemistry Letters 2003 13 18 3055 3057 (Pubitemid 36993635)
85. Witherington J., Bordas V., Gaiba A., Naylor A., Rawlings A. D., Slingsby B. P., Smith D. G., Takle A. K., Ward R. W., 6-Heteroaryl-pyrazolo[3,4-b] pyridines: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3) Bioorganic and Medicinal Chemistry Letters 2003 13 18 3059 3062 (Pubitemid 36993636)
86. Uno Y., Iwashita H., Tsukamoto T., Uchiyama N., Kawamoto T., Kori M., Nakanishi A., Efficacy of a novel, orally active GSK-3 inhibitor 6-Methyl-N-[3-[[3-(1-methylethoxy)propyl]carbamoyl]-1H-pyrazol-4-yl] pyridine-3-carboxamide in tau transgenic mice Brain Research 2009 1296 148 163
87. Kees K. L., Caggiano T. J., Steiner K. E., Fitzgerald J. J. Jr., Kates M. J., Christos T. E., Kulishoff J. M. Jr., Moore R. D., McCaleb M. L., Studies on new acidic azoles as glucose-lowering agents in obese, diabetic db/db mice Journal of Medicinal Chemistry 1995 38 4 617 628
88. Kees K. L., Fitzgerald J. J. Jr., Steiner K. E., Mattes J. F., Mihan B., Tosi T., Mondoro D., McCaleb M. L., New potent antihyperglycemic agents in db/db mice: synthesis and structure-activity relationship studies of (4-substituted benzyl)(trifluoromethyl)pyrazoles and -pyrazolones Journal of Medicinal Chemistry 1996 39 20 3920 3928 (Pubitemid 26327429)
89. Bebernitz G. R., Argentieri G., Battle B., Brennan C., Balkan B., Burkey B. F., Eckhardt M., Gao J., Kapa P., Strohschein R. J., Schuster H. F., Wilson M., Xu D. D., The effect of 1,3-diaryl-[1H]-pyrazole-4-acetamides on glucose utilization in ob/ob mice Journal of Medicinal Chemistry 2001 44 16 2601 2611 (Pubitemid 32852150)
90. Shen D. M., Brady E. J., Candelore M. R., Dallas-Yang Q., Ding V. D. H., Feeney W. P., Jiang G., McCann M. E., Mock S., Qureshi S. A., Saperstein R., Shen X., Tong X., Tota L. M., Wright M. J., Yang X., Zheng S., Chapman K. T., Zhang B. B., Tata J. R., Parmee E. R., Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core Bioorganic and Medicinal Chemistry Letters 2011 21 1 76 81
91. Peat A. J., Garrido D., Boucheron J. A., Schweiker S. L., Dickerson S. H., Wilson J. R., Wang T. Y., Thomson S. A., Novel GSK-3 inhibitors with improved cellular activity Bioorganic and Medicinal Chemistry Letters 2004 14 9 2127 2130 (Pubitemid 38481375)
92. Lum C., Kahl J., Kessler L., Kucharski J., Lundstrom J., Miller S., Nakanishi H., Pei Y., Pryor K., Roberts E., Sebo L., Sullivan R., Urban J., Wang Z., 2,5-Diaminopyrimidines and 3,5-disubstituted azapurines as inhibitors of glycogen synthase kinase-3 (GSK-3) Bioorganic and Medicinal Chemistry Letters 2008 18 12 3578 3581 (Pubitemid 351787556)
93. Aronov A. M., Qing T., Martinez-Botella G., Bemis G. W., Cao J., Chen G., Ewing N. P., Ford P. J., Germann U. A., Green J., Hale M. R., Jacobs M., Janetka J. W., Maltais F., Markland W., Namchuk M. N., Nanthakumar S., Poondru S., Straub J., ter Haar E., Xie X., Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control Journal of Medicinal Chemistry 2009 52 20 6362 6368
94. Ring D. B., Johnson K. W., Henriksen E. J., Nuss J. M., Goff D., Kinnick T. R., Ma S. T., Reeder J. W., Samuels I., Slabiak T., Wagman A. S., Hammond M. E. W., Harrison S. D., Selective glycogen synthase kinase-3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo Diabetes 2003 52 3 588 595 (Pubitemid 36323563)
95. Maeda Y., Nakano M., Sato H., Miyazaki Y., Schweiker S. L., Smith J. L., Truesdale A. T., 4-Acylamino-6-arylfuro[2,3-d]pyrimidines: potent and selective glycogen synthase kinase-3 inhibitors Bioorganic and Medicinal Chemistry Letters 2004 14 15 3907 3911 (Pubitemid 38844393)
96. Miyazaki Y., Maeda Y., Sato H., Nakano M., Mellor G. W., Rational design of 4-amino-5,6-diaryl-furo[2,3-d]pyrimidines as potent glycogen synthase kinase-3 inhibitors Bioorganic and Medicinal Chemistry Letters 2008 18 6 1967 1971 (Pubitemid 351391844)
97. Bebbington D., H. Binch, Knegtel R., Pyrazole compounds useful as protein kinase inhibitors US 2003 6660731 B2 Vertex Pharmaceuticals Inc.
98. Bebbington D., Binch H., Knegtel R., Fused pyrimidyl pyrazole compounds useful as protein kinase inhibitors US 2006 7008948 B2 Vertex Pharmaceuticals Inc.
99. Bebbington D., Charrier J., Pyrazole compounds useful as protein kinase inhibitors US 2003 6656939 B2 Vertex Pharmaceuticals Inc.
100. Bebbington D., Charrier J., Davies R., Pyrazole compounds useful as protein kinase inhibitors US 2006 6989385 B2 Vertex Pharmaceuticals Inc.
101. Bebbington D., Charrier J., Davies R., Pyrazole compounds useful as protein kinase inhibitors WO 2002 2002/059111 A2 Vertex Pharmaceuticals Inc.
102. Bebbington D., Charrier J., Davies R., Pyrazole compounds useful as protein kinase inhibitors US 2003 6653301 B2 Vertex Pharmaceuticals Inc.
103. Bebbington D., Charrier J., Golec J., Miller A., Knegtel R., Pyrazole compounds useful as protein kinase inhibitors WO 2002 2002/057259 A2 Vertex Pharmaceuticals Inc.
104. Bebbington D., Charrier J., Golec J., Miller A., Knegtel R., Pyrazole compounds useful as protein kinase inhibitors US 2003 6664247 B2 Vertex Pharmaceuticals Inc.
105. Bebbington D., Charrier J., Golec J., Pierard F., Pyrazole compounds useful as protein kinase inhibitors US 2004 6727251 B2 Vertex Pharmaceuticals Inc.
106. Bebbington D., Charrier J., Golec J., Pierard F., Pyrazole compounds useful as protein kinase inhibitors US 2008 7427681 B2 Vertex Pharmaceuticals Inc.
107. Davies R., Bebbington D., Knegtel R., Fusion joining device for plastic tubes US 2008 39081 B2 Vertex Pharmaceuticals Inc.
108. Davies R., Li P., Golec J., Charrier J., Knegtel R., Bebbington D., Pyrazole compounds useful as protein kinase inhibitors US 2003 6610677 B2 Vertex Pharmaceuticals Inc.
109. Freyne E., Love C., Cooymans L., Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors US 2008 7449465 B2 Janssen Pharmaceutica
110. Freyne E., Love C., Cooymans L., Triazolopyrimidine derivatives as glycogen synthase kinase-3 inhibitors US 2009 7560458 B2 Janssen Pharmaceutica
111. Garcia A., Gallet T., Taki Li A., 2-pyridinyl-6,7,8,9- tetrahydropyrimido[1,2-a] pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1, 2-a] pyrimidin-5(1H)one derivatives US 2009 7566720 B2 Sanofi-Aventis Mitsubishi Pharma Corporation
112. George P., Lochead A., Saady M., Slowinski F., Yaiche P., Substituted 8′-pyridinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2-a] pyrimidin-6-one and 8′-pyrimidinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2-a] pyrimidin-6-one derivatives US 2009 7507743 B2 Sanofi-Aventis Mitsubishi Pharma Corporation
113. Goff D., Harrison S., Nuss J., Ring D., Zhou X., Inhibitors of glycogen synthase kinase 3 US 2002 6417185 B1 Chiron Corporation
114. Kataoka K., Kosugi T., Ishii T., Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors US 2009 7528140 B2 Teijin Limited
115. Kataoka K., Kosugi T., Ishii T., Pyrrolopyrimidine derivative EP 2004 1477490 A1 Teijin Limited
116. Knegtel R., Bebbington D., Binch H., Pyrazole compounds useful as protein kinase inhibitors US 2003 6613776 B2 Vertex Pharmaceuticals Inc.
117. Lochead A., Marguerie S., Saady M., Yaiche P., 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin- 5(1h)-one derivatives US 2009 7608624 B2 Sanofi-Aventis Mitsubishi Pharma Corporation
118. Nakano M., Maeda Y., Novel chemical compounds WO 2005 2005/061516 A1 Smithkline Beecham Corporation
119. Nuss J., Harrison S., Ring D., Inhibitors of glycogen synthase kinase-3 US 2002 6489344 B1 Chiron Corporation
120. Nuss J., Harrison S., Ring D., Inhibitors of glycogen synthase kinase-3 US 2006 7037918 B2 Chiron Corporation
121. Nuss J., Harrison S., Ring D., Inhibitors of glycogen synthase kinase-3 US 2006 7045519 B2 Chiron Corporation
122. Tsutsumi T., Sugiura S., Koga M., Substituted pyrrolo[3,2-d]pyrimidine derivatives US 2009 7557113 B2 Teijin Pharma Limited
123. Olesen P. H., Sorensen A. R., Urso B., Kurtzhals P., Bowler A. N., Ehrbar U., Hansen B. F., Synthesis and in vitro characterization of 1-(4-aminofurazan-3-yl)-5-dialkylaminomethyl-1H-[1,2,3]triazole-4-carboxylic acid derivatives. A new class of selective GSK-3 inhibitors Journal of Medicinal Chemistry 2003 46 15 3333 3341 (Pubitemid 36842418)
124. Bandarage U., Hare B., Parsons J., Pham L., Marhefka C., Bemis G., Tang Q., Moody C. S., Rodems S., Shah S., Adams C., Bravo J., Charonnet E., Savic V., Come J. H., Green J., 4-(Benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: potent and selective p70S6 kinase inhibitors Bioorganic and Medicinal Chemistry Letters 2009 19 17 5191 5194
125. Saitoh M., Kunitomo J., Kimura E., Hayase Y., Kobayashi H., Uchiyama N., Kawamoto T., Tanaka T., Mol C. D., Dougan D. R., Textor G. S., Snell G. P., Itoh F., Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase- Bioorganic and Medicinal Chemistry 2009 17 5 2017 2029
126. Saitoh M., Kunitomo J., Kimura E., Iwashita H., Uno Y., Onishi T., Uchiyama N., Kawamoto T., Tanaka T., Mol C. D., Dougan D. R., Textor G. P., Snell G. P., Takizawa M., Itoh F., Kori M., 2-{3-[4-(Alkylsulfinyl)phenyl]-1- benzofuran-5-yl}-5-methyl-1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase- with good brain permeability Journal of Medicinal Chemistry 2009 52 20 6270 6286
127. Onishi T., Iwashita H., Uno Y., Kunitomo J., Saitoh M., Kimura E., Fujita H., Uchiyama N., Kori M., Takizawa M., A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S)- methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3, 4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease Journal of Neurochemistry 2011 119 6 1330 1340
128. Khanfar M. A., Hill R. A., Kaddoumi A., El Sayed K. A., Discovery of novel GSK- inhibitors with potent in vitro and in vivo activities and excellent brain permeability using combined ligand- and structure-based virtual screening Journal of Medicinal Chemistry 2010 53 24 8534 8545
129. Koryakova A. G., Ivanenkov Y. A., Ryzhova E. A., Bulanova E. A., Karapetian R. N., Mikitas O. V., Katrukha E. A., Kazey V. I., Okun I., Kravchenko D. V., Lavrovsky Y. V., Korzinov O. M., Ivachtchenko A. V., Novel aryl and heteroaryl substituted N-[3-(4-phenylpiperazin-1-yl)propyl]-1,2,4- oxadiazole-5-carboxamides as selective GSK-3 inhibitors Bioorganic and Medicinal Chemistry Letters 2008 18 12 3661 3666 (Pubitemid 351787547)
130. Loge C., Testard A., Thiery V., Lozach O., Blairvacq M., Robert J. M., Meijer L., Besson T., Novel 9-oxo-thiazolo[5,4-f]quinazoline-2-carbonitrile derivatives as dual cyclin-dependent kinase 1 (CDK1)/glycogen synthase kinase-3 (GSK-3) inhibitors: synthesis, biological evaluation and molecular modeling studies European Journal of Medicinal Chemistry 2008 43 7 1469 1477 (Pubitemid 351890437)
131. Bhat R., Xue Y., Berg S., Hellberg S., Ormo M., Nilsson Y., Radesater A. C., Jerning E., Markgren P. O., Borgegard T., Nylof M., Gimenez-Cassina A., Hernandez F., Lucas J. J., Diaz-Nido J., Avila J., tructural insights and biological effects of glycogen synthase kinase-3-specific inhibitor AR-A014418 The Journal of Biological Chemistry 2003 278 46 45937 45945 (Pubitemid 37432740)
132. Noble W., Planel E., Zehr C., Olm V., Meyerson J., Suleman F., Gaynor K., Wang L., LaFrancois J., Feinstein B., Burns M., Krishnamurthy P., Wen Y., Bhat R., Lewis J., Dickson D., Duff K., Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo Proceedings of the National Academy of Sciences of the United States of America 2005 102 19 6990 6995 (Pubitemid 40675429)
133. Lo Monte F., Kramer T., Bolander A., Plotkin B., Eldar-Finkelman H., Fuertes A., Dominguez J., Schmidt B., Synthesis and biological evaluation of glycogen synthase kinase-3 (GSK-3) inhibitors: an fast and atom efficient access to 1-aryl-3-benzylureas Bioorganic and Medicinal Chemistry Letters 2011 21 18 5610 5615
134. Shin D., Lee S. C., Heo Y. S., Lee W. Y., Cho Y. S., Kim Y. E., Hyun Y. L., Cho J. M., Lee Y. S., Ro S., Design and synthesis of 7-hydroxy-1H- benzoimidazole derivatives as novel inhibitors of glycogen synthase kinase- Bioorganic and Medicinal Chemistry Letters 2007 17 20 5686 5689 (Pubitemid 47398948)
135. Voigt B., Krug M., Schachtele C., Totzke F., Hilgeroth A., Probing novel 1-aza-9-oxafluorenes as selective GSK- inhibitors ChemMedChem 2008 3 1 120 126
136. Chauhan N. B., Siegel G. J., Feinstein D. L., Propentofylline attenuates tau hyperphosphorylation in Alzheimer's Swedish mutant model Tg2576 Neuropharmacology 2005 48 1 93 104 (Pubitemid 40022919)
137. Arnost M., Pierce A., ter Haar E., Lauffer D., Madden J., Tanner K., Green J., 3-Aryl-4-(arylhydrazono)-1H-pyrazol-5-ones: highly ligand efficient and potent inhibitors of GSK Bioorganic and Medicinal Chemistry Letters 2010 20 5 1661 1664
138. Chen W., Gaisina I. N., Gunosewoyo H., Malekiani S. A., S. A. Hanania, Hanania T., Kozikowski A. P., Structure-guided design of a highly selective glycogen synthase kinase-3 inhibitor: a superior neuroprotective pyrazolone showing antimania effects ChemMedChem 2011 6 1587 1592
139. Khanfar M. A., Asal B. A., Mudit M., Kaddoumi A., El Sayed K. A., The marine natural-derived inhibitors of glycogen synthase kinase- phenylmethylene hydantoins: in vitro and in vivo activities and pharmacophore modeling Bioorganic and Medicinal Chemistry 2009 17 16 6032 6039
140. Coffman K., Brodney M., Cook J., 6-amino-4-(pyrimidin-4-yl)pyridones: novel glycogen synthase kinase-3 inhibitors Bioorganic and Medicinal Chemistry Letters 2011 21 1429 1433
141. Hamann M., Alonso D., Martin-Aparicio E., Fuertes A., Perez-Puerto M. J., Castro A., Morales S., Navarro M. L., Del Monte-Milln M., Medina M., Pennaka H., Balaiah A., Peng J., Cook J., Wahyuono S., Martinez A., Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease Journal of Natural Products 2007 70 9 1397 1405 (Pubitemid 47584577)
142. Gompel M., Leost M., de Kier Joffe E. B., Puricelli L., Hernandez Franco L., Palermo J., Meijer L., Meridianins, a new family of protein kinase inhibitors isolated from the ascidian Aplidium meridianum Bioorganic and Medicinal Chemistry Letters 2004 14 7 1703 1707 (Pubitemid 38340670)
143. Meijer L., Thunnissen A. M. W. H., White A. W., Garnier M., Nikolic M., Tsai L. H., Walter J., Cleverley K. E., Salinas P. C., Wu Y. Z., Biernat J., Mandelkow E. M., Kim S. H., Pettit G. R., Inhibition of cyclin-dependent kinases, GSK- and CK1 by hymenialdisine, a marine sponge constituent Chemistry and Biology 2000 7 1 51 63 (Pubitemid 30141925)
144. Zhang N., Zhong R., Yan H., Jiang Y., Structural features underlying selective inhibition of GSK3 by dibromocantharelline: implications for rational drug design Chemical Biology and Drug Design 2011 77 3 199 205
145. Pande V., Ramos M. J., Structural basis for the GSK- binding affinity and selectivity against CDK-2 of 1-(4-aminofurazan-3yl)-5-dialkylaminomethyl-1H-[1, 2,3] triazole-4-carboxylic acid derivatives Bioorganic and Medicinal Chemistry Letters 2005 15 23 5129 5135 (Pubitemid 41463633)
146. ter Haar E., Coll J. T., Austen D. A., Hsiao H. M., Swenson L., Jain J., Structure of GSK reveals a primed phosphorylation mechanism Nature Structural Biology 2001 8 7 593 596 (Pubitemid 32613006)
147. Gotz J., Ittner L. M., Animal models of Alzheimer's disease and frontotemporal dementia Nature Reviews Neuroscience 2008 9 7 532 544 (Pubitemid 351873467)
148. Iijima-Ando K., Iijima K., Transgenic drosophila models of Alzheimer's disease and tauopathies Brain Structure and Function 2010 214 2-3 245 262
149. Wentzell J., Kretzschmar D., Alzheimer's disease and tauopathy studies in flies and worms Neurobiology of Disease 2010 40 1 21 28
150. Lucas J. J., Hernandez F., Gomez-Ramos P., Moran M. A., Hen R., Avila J., Decreased nuclear -catenin, tau hyperphosphorylation and neurodegeneration in GSK-3 conditional transgenic mice The EMBO Journal 2001 20 1-2 27 39 (Pubitemid 32099099)
151. Perez M., Ribe E., Rubio A., Lim F., Moran M. A., Ramos P. G., Ferrer I., Isla M. T. G., Avila J., Characterization of a double (amyloid precursor protein-tau) transgenic: tau phosphorylation and aggregation Neuroscience 2005 130 2 339 347 (Pubitemid 40125472)
152. Ribe E. M., Perez M., Puig B., Gich I., Lim F., Cuadrado M., Sesma T., Catena S., Sanchez B., Nieto M., Gomez-Ramos P., Moran M. A., Cabodevilla F., Samaranch L., Ortiz L., Perez A., Ferrer I., Avila J., Gomez-Isla T., Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice Neurobiology of Disease 2005 20 3 814 822 (Pubitemid 41619357)
153. Terwel D., Muyllaert D., Dewachter I., Borghgraef P., Croes S., devijver H., van Leuven F., Amyloid activates GSK- to aggravate neuronal tauopathy in bigenic mice American Journal of Pathology 2008 172 3 786 798 (Pubitemid 351354550)
154. Lewis J., Dickson D. W., Lin W. L., Chisholm L., Corral A., Jones G., Yen S. H., Sahara N., Skipper L., Yager D., Eckman C., Hardy J., Hutton M., McGowan E., Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP Science 2001 293 5534 1487 1491 (Pubitemid 32801551)
155. Oddo S., Caccamo A., Shepherd J. D., Murphy M. P., Golde T. E., Kayed R., Metherate R., Mattson M. P., Akbari Y., LaFerla F. M., Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular A and synaptic dysfunction Neuron 2003 39 3 409 421 (Pubitemid 36937044)
156. Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., van Slegtenhorst M., Gwinn-Hardy K., Murphy M. P., Baker M., Yu X., Duff K., Hardy J., Corral A., Lin W. L., Yen S. H., Dickson D. W., Davies P., Hutton M., Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L)tau protein Nature Genetics 2000 25 4 402 405 (Pubitemid 32983430)
157. Paquet D., Bhat R., Sydow A., Mandelkow E. M., Berg S., Hellberg S., Falting J., Distel M., Koster R. W., Schmid B., Haass C., A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation Journal of Clinical Investigation 2009 119 5 1382 1395
158. Paquet D., Schmid B., Haass C., Transgenic zebrafish as a novel animal model to study tauopathies and other neurodegenerative disorders in vivo Neurodegenerative Diseases 2010 7 13 99 102
159. Okawa Y., Ishiguro K., Fujita S. C., Stress-induced hyperphosphorylation of tau in the mouse brain The FEBS Letters 2003 535 13 183 189 (Pubitemid 36126378)
160. Yoshida S., Maeda M., Kaku S., Ikeya H., Yamada K., Nakaike S., Lithium inhibits stress-induced changes in tau phosphorylation in the mouse hippocampus Journal of Neural Transmission 2006 113 11 1803 1814 (Pubitemid 44657677)
161. Leroy K., Brion J. P., Developmental expression and localization of glycogen synthase kinase- in rat brain Journal of Chemical Neuroanatomy 1999 16 4 279 293 (Pubitemid 29296952)
162. Takahashi M., Tomizawa K., Ishiguro K., Distribution of tau protein kinase I/glycogen synthase kinase-, phosphatases 2A and 2B, and phosphorylated tau in the developing rat brain Brain Research 2000 857 1-2 193 206 (Pubitemid 30107806)
163. Min S. H., Cho J. S., Oh J. H., Shim S. B., Hwang D. Y., Lee S. H., Jee S. W., Lim H. J., Kim M. Y., Sheen Y. Y., Lee S. H., Kim Y. K., Tau and GSK dephosphorylations are required for regulating Pin1 phosphorylation Neurochemical Research 2005 30 8 955 961 (Pubitemid 41570030)
164. Sato N., Meijer L., Skaltsounis L., Greengard P., Brivanlou A. H., Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor Nature Medicine 2004 10 1 55 63 (Pubitemid 38524699)
165. Gould T. D., Gray N. A., Manji H. K., Effects of a glycogen synthase kinase-3 inhibitor, lithium, in adenomatous polyposis coli mutant mice Pharmacological Research 2003 48 1 49 53 (Pubitemid 36593358)
166. Martinez A., Castro A., Medina M., Glycogen Synthase Kinase-3 (GSK-3) and Its Inhibitors 2006 Hoboken, NJ, USA John Wiley Sons
167. Martinez A., Gil C., Perez D. I., Glycogen synthase kinase-3 inhibitors in the next horizon for Alzheimer's disease treatment International Journal of Alzheimer's Disease 2011 2011 7
168. Alon L. T., Pietrokovski S., Barkan S., Selective loss of glycogen synthase kinase-3 in birds reveals distinct roles for GSK-3 isozymes in tau phosphorylation The FEBS Letters 2011 585 8 1158 1162
169. Phiel C. J., Wilson C. A., Lee V. M. Y., Klein P. S., GSK-3 regulates production of Alzheimer's disease amyloid- peptides Nature 2003 423 6938 435 439 (Pubitemid 36626994)
170. Davis M. I., Hunt J. P., Herrgard S., Ciceri P., Wodicka L. M., Pallares G., Hocker M., Treiber D. K., Zarrinkar P. P., Comprehensive analysis of kinase inhibitor selectivity Nature Biotechnology 2011 29 11 1046 1051
171. Rauh D., Inaktive Kinasekonformationen stabilisieren Nachrichten aus der Chemie 2010 58 2 118 121
172. Okada K., Sato T., Kohno Y., Nomura M., 7-Cycloalkylaminoquinolones as GSK-3 inhibitors WO 2010 2010/104205 A1 Kyorin Pharmaceutical Company Limited
173. Turner S. C., Bakker M. H. M., Hornberger W., Wolter F. E., Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors WO 2010 2010/109005 A1 Abbott GmbH Co. KG.